Title Page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 1, 2015 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - September 1, 2015 Category: Cancer & Oncology Source Type: research
Infectious thoracic disease in Patients with neutropenia
Infectious diseases of the chest are some of the most frequent conditions to complicate neutropenia. Some of these diseases, such as pneumonia, are familiar to most physicians, but may have atypical presentations in the setting of neutropenia and therefore be difficult to diagnose. Others, such as infectious esophagitis, are rare in the general population and so may go unrecognized when presenting in an immunocompromised individual. As a result, a high index of suspicion must be maintained for infectious thoracic diseases in any patient with neutropenia. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - August 14, 2015 Category: Cancer & Oncology Authors: Simon R. Turner, Basil S. Nasir Source Type: research
Neutropenia: A nursing perspective
Neutropenia is the most common dose-limiting toxicity of chemotherapy. It is considered an unpreventable side effect of many types of cancer treatment. It may be a side effect of therapy or a planned aspect of a conditioning regimen for bone marrow or hematopoietic stem cell transplantation (HSCT).1 The definition of neutropenia differs among institutions, ranging from an absolute neutrophil count (ANC) of less than 500 cells/mm3 to less than 1500 cells/mm3.2–4 Neutropenia can lead to infection, increased length of stay (LOS), delay, reduction, or discontinuation of cancer treatment, and increased morbidity and mortality...
Source: Current Problems in Cancer - July 20, 2015 Category: Cancer & Oncology Authors: Roberta Kaplow, Renee Spinks Source Type: research
Foreword
Although a multitude of novel and noncytotoxic therapeutic alternatives continue to evolve, a significant number of patients still receive treatment that leads to severe neutropenia. In fact, the majority of hospitalized oncology patients are at least modestly neutropenic for part of their stay. The magnitude of the problem is real and managing patients with neutropenia is unique. The effect of neutropenia is felt on all disciplines: radiation oncology, surgical oncology, and medical oncology, as well as by both physicians and nurses. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 18, 2015 Category: Cancer & Oncology Authors: Keith A. Delman Source Type: research
Foreward
While a multitude of novel, non-cytotoxic therapeutic alternatives continue to evolve, a significant number of patients still receive treatment that leads to severe neutropenia. In fact, the majority of hospitalized oncology patients are at least modestly neutropenic for part of their stay. The magnitude of the problem is real and managing patients with neutropenia is unique. The impact of neutropenia is felt on all disciplines: radiation oncology, surgical oncology and medical oncology, as well as by both physicians and nurses. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 18, 2015 Category: Cancer & Oncology Authors: Keith A. Delman Source Type: research
Radiation Therapy and Neutropenia
There is a complex relationship between radiation therapy (RT) and the hematopoietic system that depends on concepts such as irradiated volume, RT dose, dose rate, specific radiation modality, and interactions with chemotherapy in cases of combined modality therapy. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 18, 2015 Category: Cancer & Oncology Authors: RS. Prabhu, RJ. Cassidy, JC. Landry Source Type: research
Cutaneous Angiosarcoma
Angiosarcomas are rare and aggressive tumors of vascular or lymphatic origin representing 1-2% of all soft tissue sarcomas[1,2]. As a group they exhibit remarkable clinical heterogeneity, occurring in any location of the body. The most common presentation is cutaneous lesion[3], most often on the face and scalp[1,4,5]. While surgical resection followed by adjuvant radiotherapy remains the optimal treatment, there is a high risk of loco-regional recurrence and many patients progress to disseminated disease. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 14, 2015 Category: Cancer & Oncology Authors: Lesly A. Dossett, Michael Harrington, C. Wayne Cruse, Ricardo J. Gonzalez Source Type: research
Basal cell carcinoma: Epidemiology, clinical and histologic features, and basic science overview
Basal cell carcinoma (BCC) is a quite ubiquitous entity in dermatology and dermatopathology, and, together with cutaneous squamous cell carcinoma (cSCC), constitutes the bulk of the so-called “nonmelanoma skin cancer” (NMSC) cases. Both BCC and cSCC arise in a similar clinical background of chronic sun damage and immunosuppression, among other risk factors. However, it is important to emphasize that BCC represents more of a locally aggressive tumor that rarely metastasizes, compared with cSCC, particularly some subtypes, which may have a higher risk of metastatic spread and even death. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 8, 2015 Category: Cancer & Oncology Authors: Carlos Prieto-Granada, Paul Rodriguez-Waitkus Source Type: research
Basal cell carcinoma: Epidemiology, clinical & histological features and basic science overview
Basal cell carcinoma (BCC) represents one of the most common malignancies in humans and, along with cutaneous squamous cell carcinoma (cSCC), constitutes the great majority of tumors seen both in dermatology clinics and dermatopathology practices. Consequentially, it is of vital importance to be acquainted with the different facets of BCC, including its epidemiology, to the varied clinical presentations with their corresponding histological subtypes to the latest advances underlying the molecular mechanisms driving the development of this neoplasm. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 8, 2015 Category: Cancer & Oncology Authors: Carlos Prieto-Granada, Paul Rodriguez-Waitkus Source Type: research
Cutaneous squamous cell carcinoma and related entities: Epidemiology, clinical and histological features and basic science overview.
Cutaneous squamous cell carcinoma (cSCC) represents only a percentage of the so-called non-melanoma skin cancers (NMSC), but it is considered the second most common human malignancy after basal cell carcinoma (BCC). In contrast to the majority of BCC cases, cSCC accounts for significant morbidity and mortality, representing the majority of metastases and deaths related to NMSC. Several cSCC types are described with a distinct group of cSCC high-risk variants being associated with significantly elevated risk of local recurrence, metastases and death. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 8, 2015 Category: Cancer & Oncology Authors: Carlos Prieto-Granada, Paul Rodriguez-Waitkus Source Type: research
Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma
Cutaneous leiomyosarcoma (LMS) and dermatofibrosarcoma protuberans (DFSP) are two rare dermal sarcomas that are locally aggressive but rarely metastasize. Both entities carry a very good long term prognosis. Our current approach to LMS and DFSP is multidisciplinary with the pathologist’s contribution just as important the surgeon’s contribution. Surgical resection is the standard of care and primary management for both DFSP and LMS. In areas approximating critical or sensitive structures (i.e., face) there is an important role for Mohs micrographic surgery. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 8, 2015 Category: Cancer & Oncology Authors: Evan S. Glazer, Carlos Prieto-Granada, Jonathan S. Zager Source Type: research
A comprehensive guide to the surgical management of nonmelanoma skin cancer
The ultimate goal in surgical management of nonmelanoma skin cancer (NMSC) is tumor eradication. Surgical procedures include Mohs micrographic surgery (MMS), surgical excision (SE), curettage and electrodessication (C&E), and cryosurgery. All of these interventions are useful tools in the surgical management of NMSC and each has its unique set of strengths and weaknesses. Tumor clearance rates, postsurgical complications, recurrence rates, cosmesis, and costs can vary greatly based on both the intervention chosen and the characteristics of the lesion being treated. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 7, 2015 Category: Cancer & Oncology Authors: Jennifer Divine, Lilia Stefaniwksy, Revati Reddy, Pamela Padilla, Thomas Hagele, Nishit S. Patel, Basil S. Cherpelis Source Type: research
An overview of the medical management of nonmelanoma skin cancer
Treatment of nonmelanoma skin cancer (NMSC) has remained confined to a very singular approach. Surgical procedures represent more than 95% of administered treatments for basal cell carcinoma (BCC). In a prospective study, 34.2% of patients underwent the Mohs surgery, 34.5% underwent simple excision, and 26.7% underwent destruction.1 However, some suggest tailoring treatment to patients’ needs and considering alternative modalities.2 Increasing research into medical therapeutics underscores this shift toward individualized and patient-centered care. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 7, 2015 Category: Cancer & Oncology Authors: Lauren Metterle, Jeffrey S. Russell, Nishit S. Patel Source Type: research
A Comprehensive Guide to the Surgical Management of Non-Melanoma Skin Cancer
The ultimate goal in surgical management of NMSC is tumor eradication. Surgical procedures include Mohs micrographic surgery (MMS), surgical excision (SE), curettage and electrodessication (C&E), and cryosurgery. All of these interventions are useful tools in the surgical management of NMSC and each has its unique set of strengths and weaknesses. Tumor clearance rates, post-surgical complications, recurrence rates, cosmesis and costs and can vary greatly based on both the intervention chosen and the characteristics of the lesion being treated. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - July 7, 2015 Category: Cancer & Oncology Authors: Jennifer Divine, Lilia Stefaniwksy, Revati Reddy, Pamela Padilla, Thomas Hagele, Nishit S. Patel, Basil S. Cherpelis Source Type: research
